Results 151 to 160 of about 36,256 (261)

Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma [PDF]

, 2015

core   +1 more source

Data from Phase II Single-arm Study of Durvalumab and Tremelimumab with Concurrent Radiotherapy in Patients with Mismatch Repair–proficient Metastatic Colorectal Cancer

, 2023
Neil H. Segal, Andrea Cercek, Geoffrey Y. Ku, Abraham J. Wu, Andreas Rimner, Danny N. Khalil, Diane Reidy‐Lagunes, John Cuaron, Jonathan T. Yang, Martin R. Weiser, Paul B. Romesser, Zsofia K. Stadler, Anna M. Varghese, Karuna Ganesh, Rona Yaeger, Louise C. Connell, David M. Faleck, Ghassan K. Abou‐Alfa, Kathleen C. Mcauliffe, Pamela Vaiskauskas, Mark L. Solter, Martinique Ogle, Matthew Adamow, Aliya Holland, Pallavi Vedantam, Phillip Wong, Taha Merghoub, Efsevia Vakiani, Travis J. Hollmann, Krishna Juluru, Joanne F. Chou, Marinela Capanu, Joseph P. Erinjeri, Stephen B. Solomon, Yoshiya Yamada, Nancy E. Kemeny, Christopher H. Crane, Leonard B. Saltz   +37 more
openalex   +1 more source

Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma [PDF]

, 2016

core   +1 more source

Supplementary Table from Phase Ia/b, Open-Label, Multicenter Study of AZD4635 (an Adenosine A2A Receptor Antagonist) as Monotherapy or Combined with Durvalumab, in Patients with Solid Tumors

, 2023
Emerson A. Lim, Johanna C. Bendell, Gerald S. Falchook, Todd M. Bauer, Charles G. Drake, Jennifer H. Choe, Daniel J. George, Janet L. Karlix, Susanna V. Ulahannan, Kris F. Sachsenmeier, Deanna L. Russell, Ganesh Moorthy, Ben S. Sidders, Elizabeth A. Pilling, Huifang Chen, Maureen M. Hattersley, Mayukh Das, Rakesh Kumar, Gayle P. Pouliot, Manish R. Patel   +19 more
openalex   +1 more source

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression [PDF]

, 2020
Siddharth Sheth, Chen Gao, Nancy K. Mueller, Natasha Angra, Ashok Gupta, Caroline Germa, Pablo Martínez, Jean‐Charles Soria   +7 more
openalex   +1 more source

Durvalumab-associated membranous nephropathy: a case report and brief literature review. [PDF]

CEN Case Rep
Mizoguchi R, Tashiro T, Sakakima M.
europepmc   +1 more source

66MO Durvalumab after radiotherapy (RT) in patients (pts) with unresectable stage III NSCLC ineligible for chemotherapy (CT): Final analysis of the phase II DUART study

Andrea Riccardo Filippi, M.R. García Campelo, J Paoli, Diane Kowalski, C. Bennati, P. Borghetti, D. Cortinovis, Angelo Delmonte, C. Genova, R. Mroz, Sergiusz Nawrocki, I. Toledano, Giuseppe Tonini, Francesco Agustoni, G. Wetherill, I. Diaz Perez, Nefeli Georgoulia, Rafał Dziadziuszko   +17 more
openalex   +1 more source

Mixed Infectious-Immune Pneumonitis Associated with PD-L1 Blockade: A Case of Durvalumab-Induced Lung Injury Complicated by Human Metapneumovirus Infection. [PDF]

J Clin Med
Pipitò L, Mazzola CV, Giacchino I, De Rosa R, Gagliardo CM, Lipari AG, Monte P, Furia F, Mannino E, Pecoraro R, Scichilone N, Cascio A.   +11 more
europepmc   +1 more source

202P: Durvalumab after definitive chemoradiation (dCRT) in non-small cell lung cancer (NSCLC) patients with actionable driver mutations [PDF]

Jol S., K.M. Cheung
openalex   +1 more source

Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors-A Turkish Oncology Group Study. [PDF]

Cancers (Basel)
Efil SC, Kus F, Koylu B, Durukan BM, Bayram S, Guzel HG, Ozturk B, Muglu H, Bilici A, Kose F, Alan O, Karapelit Agitoglu E, Guner G, Besen AA, Helvaci K, Araz M, Kacan T, Arslan C, Unal A, Eniseler EB, Biter S, Ekinci F, Aslan F, Unek IT, Tas S, Acar O, Ates O, Sakalar T, Akbas S, Karakas H, Akinci MB, Yalcin B, Yalcin S, Sendur MAN.   +33 more
europepmc   +1 more source